Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder

Isiten H. N., Cebi M., Kaya B., Metin B., Tarhan N.

CLINICAL EEG AND NEUROSCIENCE, cilt.48, sa.4, ss.246-250, 2017 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 48 Sayı: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1177/1550059416675232
  • Dergi Adı: CLINICAL EEG AND NEUROSCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.246-250
  • Anahtar Kelimeler: attention-deficit, hyperactivity disorder, EEG biomarker, methylphenidate, relative power, theta, beta ratio, DEFICIT-HYPERACTIVITY DISORDER, QUANTITATIVE EEG, RATING-SCALES, ADHD, PREVALENCE, VALIDATION, DIAGNOSIS, BOYS
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

EEG biomarkers have become increasingly used to aid in diagnosis of attention-deficit/hyperactivity disorder (ADHD). Despite several studies suggesting that EEG theta/beta ratio may help discriminating ADHD from other disorders, the effect of medications on theta/beta ratio is not known. Forty-three children with ADHD that were evaluated with quantitative EEG before and after methylphenidate were included in the study. Theta/beta ratio, theta and beta powers for whole brain, central, and frontal areas were calculated. Theta/beta power decreased significantly after treatment; however, this change was largely due to an increase in beta power, rather than a fall in theta power. The results suggest that beta power is sensitive to medication effects, while theta power remains as a trait biomarker unaffected by medication status. The value of EEG biomarkers for monitoring neuropsychological performance and clinical status should be explored by future studies.